Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/23723556.2017.1359228 http://scihub22266oqcxt.onion/10.1080/23723556.2017.1359228 C5706936!5706936!29209647     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mol+Cell+Oncol 2017 ; 4 (6): ä Nephropedia Template TP {{tp|p=29209647|t=2017. Targeting RAS ? will GPR31 deliver us a new path forward?|pdf=|usr=}}{{29209647}} gab.com Text Targeting RAS will GPR31 deliver us a new path forward JO: Mol Cell Oncol http://www.kidney.de/pget.php?&tw=1&pmid=29209647 #FOAvip Effective anti-rat sarcoma viral oncogene (RAS) therapies have remained the holy grail of cancer treatment. Mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) sustains tumorigenesis when linked to the plasma membrane (PM). The G protein-coupled receptor 31 (GPR31) is now identified to mediate KRAS membrane association and is crucial for proliferation, survival and macropinocytosis of KRAS-dependent cancer cells, suggesting that GPR31 is a druggable target for anti-RAS therapy. Twit Text FOAVip Targeting RAS will GPR31 deliver us a new path forward ????Mol Cell Oncol http://www.kidney.de/pget.php?&tw=1&pmid=29209647 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29209647 #FOAvip English Wikipedia <ref>{{Cite pmid|29209647}}</ref> Targeting RAS ? will GPR31 deliver us a new path forward? #MMPMID29209647 Fehrenbacher N; Philips MR Mol Cell Oncol 2017[]; 4 (6): ä PMID29209647show ga Effective anti-rat sarcoma viral oncogene (RAS) therapies have remained the holy grail of cancer treatment. Mutant Kirsten rat sarcoma viral oncogene homolog (KRAS) sustains tumorigenesis when linked to the plasma membrane (PM). The G protein-coupled receptor 31 (GPR31) is now identified to mediate KRAS membrane association and is crucial for proliferation, survival and macropinocytosis of KRAS-dependent cancer cells, suggesting that GPR31 is a druggable target for anti-RAS therapy. äTargeting RAS ? will GPR31 deliver us a new path forward?(epmc).pdf DeepDyve Pubget Overpricing